Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Key Inclusion Criteria:

• For patients with AMD:

• Active subfoveal choroidal neovascularization (CNV) secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA or OCT in the study eye, as determined by the investigator
• Men or women ≥50 years and older
• For patients with DME:

• Patients with clinically significant DME with central involvement (≥300 μm in the central subfield on spectral domain OCT)
• Men or women ≥18 years and older

Key Exclusion Criteria:

• For patients with neovascular AMD:

• Evidence of choroidal neovascularization (CNV) due to any cause other than AMD in either eye
• Evidence of diabetic retinopathy (DR) or DME in either eye
• For patients with DME: Evidence of neovascular AMD or CNV due to any cause in either eye
• Prior IAI in either eye
• IVT bevacizumab, ranibizumab, or pegaptanib sodium in the study eye within 8 weeks of day 1 or an AE with any of these previous treatments that would preclude administration of drug in this study
• Any prior treatment with angiopoietin inhibitors
• Any prior systemic (IV) anti-VEGF administration
• History of vitreoretinal surgery in the study eye
• Pan retinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of the screening visit
• Previous use of intraocular or periocular corticosteroids in the study eye within 4 months of screening

(The inclusion/ exclusion criteria provided above are not intended to contain all considerations relevant to a subject's potential participation in this clinical trial).